Different countries have varying responses to patent evergreening. Some jurisdictions, like India, have taken steps to limit this practice by implementing stricter patentability criteria. For instance, India's Patent Act includes a provision that prevents the patenting of new forms of known substances unless they result in significantly enhanced efficacy. This has led to legal battles between pharmaceutical companies and governments, highlighting the tension between intellectual property rights and public health.
